Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer

Abstract

TP53 signature as diagnosed using the nCounter system is not only a robust predictor of prognosis but also a potential predictor of responsiveness to immune checkpoint inhibitors.